27.10.2021 15:28

Will Pfizer (PFE) Keep the Earnings Streak Alive in Q3?

Folgen
Werbung
We expect Pfizer PFE to beat expectations when it reports third-quarter 2021 results on Nov 2, before market open. In the last reported quarter, the company beat earnings expectations by 10.31%.The drug giant’s performance has been mixed, with the company exceeding earnings expectations in three of the last four quarters while missing in one. The company has a four-quarter earnings surprise of 5.55%, on average.Pfizer Inc. Price, Consensus and EPS Surprise Pfizer Inc. price-consensus-eps-surprise-chart | Pfizer Inc. QuotePfizer’s stock has risen 18.4% this year so far compared with an increase of 11.6% for the industry.Image Source: Zacks Investment ResearchFactors to NoteA key contributor to Pfizer’s sales in the third quarter is likely to have been its and partner BioNTech’s BNTX COVID-19 vaccine, Comirnaty. Sales are expected to be higher than second-quarter sales of $7.8 billion.Higher sales of Pfizer’s key brands, Eliquis [alliance revenues from Bristol Myers BMY], Xtandi and Inlyta, and significant contribution from newer drug Vyndaqel/Vyndamax and higher biosimilar revenues are likely to have contributed to sales growth in the third quarter of 2021.Sales of Prevnar 13/Prevenar 13 vaccine, which were hurt significantly by the pandemic in the previous quarters, improved in the United States in the second quarter. We expect the positive trend to have continued in the third quarter.Ibrance sales are likely to have risen outside U.S. markets, which might have made up for lower sales in the United States.The Zacks Consensus Estimate for oncology and vaccine products is $3.19 billion and $14.51 billion, respectively.However, sales of some key drugs like Chantix in the United States and Enbrel in international markets are likely to have declined in the third quarter, continuing the trend of the past few quarters. While Chantix sales are expected to have been hurt by the loss of exclusivity, sales of Enbrel in key European markets and Japan are likely to have been hurt by biosimilar competition.R&D costs are expected to have been higher in the third quarter due to incremental spending on COVID-19 vaccines and antiviral medicines as well as other mRNA-based programs.Key Recent DevelopmentLast month, the FDA granted emergency use authorization (EUA) to a booster or “third” dose of Comirnaty for individuals 65 years and older and those in high-risk groups.The high-risk groups include individuals aged 16 to 64, at a high risk of severe COVID-19, and those whose occupation exposes them to the virus and puts them at a high risk of COVID-related complications, including severe COVID-19, like healthcare workers, teachers, and others. However, in line with the recommendation of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), the FDA did not approve the booster dose for the entire population for which Pfizer/BioNTech was seeking approval. Pfizer/BioNTech had filed its supplemental biologics license application (sBLA), seeking approval for the booster dose of Comirnaty, in people 16 years of age and older, in August.Pfizer’s pivotal phase II/III study showed that its COVID-19 vaccine was safe, well-tolerated and initiated robust neutralizing antibody responses in children 5 to 11 years of age. Data from the study cohort showed that one month of immunization with two doses of Comirnaty resulted in SARS-CoV-2–neutralizing antibody geometric mean titer levels that were non-inferior to the level achieved in individuals aged 16 to 25 years of age in the previously completed clinical study. This week, the VRBPAC voted in favor (17 to 0, with one abstention) of the FDA granting EUA to Comirnaty for kids of this age group.Earnings WhispersOur proven model predicts an earnings beat for Pfizer in the soon-to-be-reported quarter because it has the right combination of the two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely beat.Earnings ESP: Pfizer’s Earnings ESP is +2.25% as the Most Accurate Estimate of $1.11 per share is pegged higher than the Zacks Consensus Estimate of $1.08 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: Pfizer has a Zacks Rank #3Another Stock to ConsiderA biotech stock that has the right combination of elements to beat on earnings this time around is Merck MRK, which has an Earnings ESP of +2.64% and a Zacks Rank #3.The company is scheduled to report earnings on Oct 28. You can see the complete list of today’s Zacks #1 Rank stocks here.Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Quelle: Zacks

Nachrichten zu Pfizer Inc.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Pfizer Inc.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
30.11.2021Pfizer NeutralJP Morgan Chase & Co.
17.11.2021Pfizer Equal WeightBarclays Capital
05.11.2021Pfizer NeutralJP Morgan Chase & Co.
03.11.2021Pfizer Equal WeightBarclays Capital
29.07.2021Pfizer NeutralGoldman Sachs Group Inc.
03.02.2021Pfizer kaufenDZ BANK
02.12.2020Pfizer OutperformRBC Capital Markets
16.10.2020Pfizer OutperformRBC Capital Markets
09.09.2020Pfizer OutperformRBC Capital Markets
20.07.2020Pfizer OutperformRBC Capital Markets
30.11.2021Pfizer NeutralJP Morgan Chase & Co.
17.11.2021Pfizer Equal WeightBarclays Capital
05.11.2021Pfizer NeutralJP Morgan Chase & Co.
03.11.2021Pfizer Equal WeightBarclays Capital
29.07.2021Pfizer NeutralGoldman Sachs Group Inc.
03.05.2018Pfizer VerkaufenDZ BANK
16.05.2017Pfizer SellCitigroup Corp.
27.11.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
28.08.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
10.01.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pfizer Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Asiatische Börsen uneins -- Musk verkauft weitere Tesla-Aktien -- DiDi leitet Rückzug von New Yorker Börse ein -- Allianz verspricht Aktionären Dividendenwachstum

Aurubis erhöht Dividende deutlich nach höherem Gewinn. Aktie von Daimler Truck am 10. Dezember für einen Tag im DAX. US-Kongress wendet 'Shutdown' ab. Meyer Burger drosselt wegen Corona Produktion in Freiberg. US-Regierung klagt gegen Kauf des Chipdesigners Arm durch NVIDIA. Daimler-Aufsichtsrat segnet Investitionsplan für Mercedes-Benz ab

Umfrage

Wie bewerten Sie die Verhandlungsergebnisse und künftigen Pläne der Ampelkoalition?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln